Edition:
United States

MannKind Corp (MNKD.OQ)

MNKD.OQ on NASDAQ Stock Exchange Global Market

1.59USD
4:00pm EDT
Change (% chg)

$-0.02 (-1.24%)
Prev Close
$1.61
Open
$1.58
Day's High
$1.63
Day's Low
$1.57
Volume
228,198
Avg. Vol
528,679
52-wk High
$6.96
52-wk Low
$1.09

Chart for

About

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic... (more)

Overall

Beta: 2.60
Market Cap(Mil.): $221.24
Shares Outstanding(Mil.): 140.03
Dividend: --
Yield (%): --

Financials

  MNKD.OQ Industry Sector
P/E (TTM): -- 212.74 32.86
EPS (TTM): -1.20 -- --
ROI: -- -3.73 13.13
ROE: -- -5.79 15.07

BRIEF-Mannkind Q1 Loss Per Share $0.25

* Q1 REVENUE ROSE 15 PERCENT TO $3.4 MILLION Source text for Eikon: Further company coverage:

May 09 2018

BRIEF-Cipla Partners With Mannkind For Marketing, Distribution Of Afrezza In India

* PARTNERS WITH MANNKIND FOR EXCLUSIVE MARKETING, DISTRIBUTION OF AFREZZA IN INDIA

May 09 2018

BRIEF-Mannkind And Cipla Enter An Exclusive Marketing And Distribution Agreement For Afrezza® In India

* MANNKIND AND CIPLA ENTER AN EXCLUSIVE MARKETING AND DISTRIBUTION AGREEMENT FOR AFREZZA® IN INDIA

May 09 2018

BRIEF-Mannkind Announces $28.0 Million Registered Direct Offering

* MANNKIND ANNOUNCES $28.0 MILLION REGISTERED DIRECT OFFERING

Apr 06 2018

BRIEF-MannKind Restructures $79.7 Mln Debt Obligation To The Mann Group

* MANNKIND RESTRUCTURES $79.7 MILLION DEBT OBLIGATION TO THE MANN GROUP AND REDUCES PRINCIPAL OWED TO DEERFIELD BY $6.3 MILLION

Mar 12 2018

BRIEF-Mannkind Corporation Q4 Loss Per Share $0.28

* ORATION REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

Feb 27 2018

BRIEF-David Kendall Joins MannKind As Chief Medical Officer

* MANNKIND CORP - MOST RECENTLY, KENDALL SERVED AS RESEARCH PHYSICIAN AND VICE PRESIDENT OF GLOBAL MEDICAL AFFAIRS FOR LILLY DIABETES​ Source text for Eikon: Further company coverage:

Feb 06 2018

Competitors

  Price Chg
Novo Nordisk A/S (NOVOb.CO) kr.318.10 -3.45
Pfizer Inc. (PFE.N) $37.36 -0.30
Sanofi SA (SASY.PA) €72.11 -0.40
Eli Lilly And Co (LLY.N) $89.43 -0.60
Nektar Therapeutics (NKTR.OQ) $49.08 +1.20
Albireo Pharma Inc (ALBO.OQ) $32.55 -0.33

Earnings vs. Estimates